570 ENHANCER OF ZESTE HOMOLOG 2 (EZH2) IS A POWERFUL INDEPENDENT PROGNOSTIC FACTOR IN RENAL CELL CARCINOMA AND CONTRIBUTES TO CELL PROLIFERATION AND APOPTOSIS RESISTANCE IN RENAL CANCER CELLS

2010 ◽  
Vol 9 (2) ◽  
pp. 193
Author(s):  
N. Wagener ◽  
S. Macher-Goeppinger ◽  
D. Holland ◽  
I. Crnkovic-Mertens ◽  
K. Hoppe-Seyler ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Proliferation ◽  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Cancer Cells ◽  
Renal Cancer ◽  
Renal Cell ◽  
Independent Prognostic Factor ◽  
Apoptosis Resistance ◽  
Proliferation And Apoptosis

scholarly journals Circular RNA circMTO1 Suppresses RCC Cancer Cell Progression via miR9/LMX1A Axis

2020 ◽  
Vol 19 ◽  
pp. 153303382091428
Author(s):  
Kecheng Li ◽  
Cheng-Liang Wan ◽  
Yan Guo
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Proliferation ◽  
Cell Carcinoma ◽  
Cancer Cells ◽  
Renal Cancer ◽  
Renal Cell ◽  
Target Genes ◽  
Cell Function ◽  
Circular Rnas ◽  
Promoting Effect

Renal cell carcinoma is one of the most common kidney cancer, which accounts almost 90% of the adult renal malignancies worldwide. In recent years, a new class of endogenous noncoding RNAs, circular RNAs, exert important roles in cell function and certain types of pathological responses, especially in cancers, generally by acting as a microRNA sponge. Circular RNAs could act as sponge to regulate the microRNA and the target genes. However, the knowledge about circular RNAs in renal cell carcinoma remains unclear so far. In the research, we selected a highly expressed novel circular RNAs named circMTO1 in renal cell carcinomas. We investigated the roles of circMTO1 and found that circMTO1 overexpression could suppress cell proliferation and metastases in both A497 and 786-O renal cancer cells, while silencing of circMTO1 could promote the progression in SN12C and OS-RC-2 renal cancer cells. The study showed that circMTO1 acted as miR9 and miR223 sponge and inhibited their levels. Furthermore, silencing of circMTO1 in renal cell carcinoma could downregulate LMX1A, the target of miR-9, resulting in the promotion of renal cell carcinoma cell proliferation and invasion. In addition, LMX1A expression suppression induced by transfection of miR9 mimics confirmed that miR9 exerted its function in renal cell carcinoma by regulating LMX1A expression. What’s more, miR9 inhibitor and LMX1A overexpression could block the tumor-promoting effect of circMTO1 silencing. In conclusion, circMTO1 suppresses renal cell carcinoma progression by circMTO1/miR9/ LMX1A, indicating that circMTO1 may be a potential target in renal cell carcinoma therapy.

THE ENHANCER OF ZESTE HOMOLOG 2 GENE CONTRIBUTES TO CELL PROLIFERATION AND APOPTOSIS RESISTANCE IN RENAL CELL CARCINOMA CELLS

2008 ◽  
Vol 179 (4S) ◽  
pp. 88-89
Author(s):  
Nina Wagener ◽  
Daniela Holland ◽  
Irena Crnkovic-Mertens ◽  
Karin Hoppe-Seyler ◽  
Hanswalter Zentgraf ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Proliferation ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Carcinoma Cells ◽  
Apoptosis Resistance ◽  
Proliferation And Apoptosis ◽  
Enhancer Of Zeste

scholarly journals Theenhancer of zeste homolog 2gene contributes to cell proliferation and apoptosis resistance in renal cell carcinoma cells

2008 ◽  
Vol 123 (7) ◽  
pp. 1545-1550 ◽  
Author(s):  
Nina Wagener ◽  
Daniela Holland ◽  
Julia Bulkescher ◽  
Irena Crnković-Mertens ◽  
Karin Hoppe-Seyler ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Proliferation ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Carcinoma Cells ◽  
Apoptosis Resistance ◽  
Proliferation And Apoptosis

Effect of host immunity on metastatic potential in renal cell carcinoma: the assessment of optimal in vivo models to study metastatic behavior of renal cancer cells

Tumor Biology ◽  
2012 ◽  
Vol 33 (2) ◽  
pp. 551-559 ◽  
Author(s):  
Minoru Kobayashi ◽  
Tatsuo Morita ◽  
Nicole A. L. Chun ◽  
Aya Matsui ◽  
Masafumi Takahashi ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Cell Carcinoma ◽  
Cancer Cells ◽  
Renal Cancer ◽  
Renal Cell ◽  
Metastatic Potential ◽  
Host Immunity ◽  
In Vivo Models ◽  
Metastatic Behavior

Hilar Location is an Independent Prognostic Factor for Recurrence in T1 Renal Cell Carcinoma After Nephrectomy

2014 ◽  
Vol 22 (1) ◽  
pp. 344-350 ◽  
Author(s):  
Myungsun Shim ◽  
Cheryn Song ◽  
Sejun Park ◽  
Aram Kim ◽  
Seung-Kwon Choi ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Renal Cell ◽  
Independent Prognostic Factor

Preoperative serum cholesterol is an independent prognostic factor for patients with renal cell carcinoma (RCC)

2014 ◽  
Vol 115 (3) ◽  
pp. 397-404 ◽  
Author(s):  
Michela de Martino ◽  
Carmen V. Leitner ◽  
Christoph Seemann ◽  
Sebastian L. Hofbauer ◽  
Ilaria Lucca ◽  
...  
Keyword(s):  
Renal Cell Carcinoma ◽  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Serum Cholesterol ◽  
Renal Cell ◽  
Independent Prognostic Factor ◽  
Preoperative Serum

Can Systemic Immune-Inflammation Index Create a New Perspective for the IMDC Scoring System in Patients with Metastatic Renal Cell Carcinoma?

2021 ◽  
pp. 1-8
Author(s):  
Fatma Bugdayci Basal ◽  
Cengiz Karacin ◽  
Irem Bilgetekin ◽  
Omur Berna Oksuzoglu
Keyword(s):  
Renal Cell Carcinoma ◽  
Prognostic Factor ◽  
Regression Model ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Cox Regression ◽  
Independent Prognostic Factor ◽  
Cox Regression Model ◽  
Kaplan Meier

Introduction: The aim of the study was to evaluate impact of the systemic immune-inflammation index (SII) on prognosis and survival within the International Metastatic Renal Cell Carcinoma Database Consortium (IMDC) score groups. Methods: The records of 187 patients with metastatic renal cell carcinoma (RCC) were reviewed retrospectively. The SII was calculated as follows: SII = Neutrophil × Platelet/Lymphocyte. The patients were categorized into 2 groups based on a median SII of 730 (×109 per 1 L) as SII low (<730) and SII high (≥730). The Kaplan-Meier method was used for survival analysis and a Cox regression model was utilized to determine independent predictors of survival. Results: The median age was 61 years (range: 34–86 years). Kaplan-Meier tests revealed significant differences in survival between the SII-low and SII-high levels (27.0 vs. 12.0 months, respectively, p < 0.001). The Cox regression model revealed that SII was an independent prognostic factor. The implementation of the log-rank test in the IMDC groups according to the SII level provided the distinction of survival in the favorable group (SII low 49.0 months vs. SII high 11.0 months, p < 0.001), in the intermediate group (SII low 26.0 vs. SII high 15.0 months, p = 0.007), and in the poor group (SII low 19.0 vs. SII high 6.0 months, p = 0.019). Conclusion: The SII was an independent prognostic factor and provided significant differences in survival for the favorable, intermediate, and poor IMDC groups. Thus, the SII added to the IMDC score may be clinically beneficial in predicting survival.

Pre-existing hypertension is an independent prognostic factor in metastatic renal cell carcinoma (mRCC) patients treated with sunitinib (SU).

2014 ◽  
Vol 32 (15_suppl) ◽  
pp. 4573-4573
Author(s):  
Lisa Derosa ◽  
Hassane Izzedine ◽  
Gwenael Le Teuff ◽  
Laurence Albiges ◽  
Bernard Escudier
Keyword(s):  
Renal Cell Carcinoma ◽  
Prognostic Factor ◽  
Cell Carcinoma ◽  
Metastatic Renal Cell Carcinoma ◽  
Renal Cell ◽  
Independent Prognostic Factor
Sign in / Sign up

Export Citation Format

Share Document